Intranasal Delivery of Neuropeptides

Methods in Molecular Biology

Volumn 789, Issue , 2011, Pages 303-312

  Veronesi, Michael C ^a   Kubek, Daniel J ^a   Kubek, Michael J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery; Intranasal delivery; Nasal cannula; Neuropeptides; Olfactory neuroepithelium

Indexed keywords

NEUROPEPTIDE;

ANIMAL; ARTICLE; INTRANASAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; OLFACTORY EPITHELIUM; RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; NEUROPEPTIDES; OLFACTORY MUCOSA; RATS;

ANIMALIA; RATTUS;

EID: 80054753934     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-310-3_20     Document Type: Chapter

References (43)

1. Chow, H.S., Chen, Z., and Matsuura, G.T. (1999) Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J. Pharm. Sci. 88, 754–758.
2. Hussain, A.A. (1998) Intranasal drug delivery. Adv. Drug Deliv. Rev. 29, 39–49.
3. Sakane, T., Akizuki, M., Taki, Y., Yamashita, S., Sezaki H., and Nadai, T. (1995) Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J. Pharm. Pharmacol. 47, 379–381.
4. Sakane, T., Akizuki, M., Yamashita, S., Sezaki, H., Nadai, T. (1994) Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug. J. Pharm. Pharmacol. 46, 378–379.
5. Sakane, T., Akizuki, M., Yoshida, M., Yamashita, S., Nadai, T., et al. (1991) Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J. Pharm. Pharmacol. 43, 449–451.
6. Agarwal, V., and Mishra, B. (1999) Recent trends in drug delivery systems: intranasal drug delivery. Indian J. Exp. Biol. 37, 6–16.
7. Lewis, J.L., and Dahl A.R. (1995) Ofactory mucosa: composition, enzymatic localization, and metabolism. In: Handbook of olfaction and gustation ed. RL Doty, pp. 33–52. New York: Marcel Dekker, Inc.
8. Kubek, M., Yard, M., Lahiri, D.K., and Domb, A.J. (2007) Characterization of Novel Intranasal Sustained-Release Nanoparticles for Delivery of Neuropeptides to the Brain. In Nanoparticles for pharmaceutical applications, ed. TY Domb A, Ravi Kumar NV, pp. 73–84. New York: American Scientific Publishers.
9. Kubek, M.J., Domb, A.J., and Veronesi, M.C. (2009) Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics 6, 359–371.
10. Egleton, R.D., and Davis, T.P. (2005) Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2, 44–53.
11. Hökfelt, T., Broberger, C., Xu, Z.Q., Sergeyev, V., Ubink, R., and Diez, M. (2000) Neuropeptides--an overview. Neuropharmacology 39, 1337–1356.
12. Strand, F.L. (2005) The neuropeptide concept and the evolution of neuropeptides In Neuropeptides: Regulators of Physiological Processes, ed. FL Strand, pp. 3–18. Cambridge: MIT Press.
13. Liu, X.F., Fawcett, J.R., Thorne, R.G., DeFor, T.A., and Frey, W.H, 2nd. (2001) Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J. Neurol. Sci. 187, 91–97.
14. Semkova, I., and Krieglstein, J. (1999) Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain Res. Brain Res. Rev. 30, 176–188.
15. Bjorbaek, C., and Kahn, B.B. (2004) Leptin signaling in the central nervous system and the periphery. Recent Prog. Horm. Res. 59, 305–331.
16. Gale, S.M., Castracane, V.D., and Mantzoros, C.S. (2004) Energy homeostasis, obesity and eating disorders: recent advances in endocrinology. J. Nutr. 134, 295–298.
17. Gentilucci, L. (2004) New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr. Top. Med. Chem. 4, 19–38.
18. Lim, K.C., Lim, S.T., and Federoff, H.J. (2003) Neurotrophin secretory pathways and synaptic plasticity. Neurobiol. Aging 24, 1135–1145.
19. Claes, S.J. (2004) Corticotropin-releasing hormone (CRH) in psychiatry: from stress to psy-chopathology. Ann. Med. 36, 50–61.
20. Datar, P., Srivastava, S., Coutinho, E., and Govil G. (2004) Substance P: structure, function, and therapeutics. Curr. Top. Med. Chem. 4, 75–103.
21. Strohle, A., and Holsboer, F. (2003) Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 36, S207–214.
22. Balasubramaniam, A. (2002) Clinical potentials of neuropeptide Y family of hormones. Am. J. Surg. 183, 430–434.
23. Binaschi, A., Bregola, G., and Simonato, M. (2003) On the role of somatostatin in seizure control: clues from the hippocampus. Rev. Neurosci. 14, 285–301.
24. Kubek, M.J., and Garg, B.P. (2002) Thyrotropin-releasing hormone in the treatment of intractable epilepsy. Pediatr. Neurol. 26, 9–17.
25. Veronesi, M.C., Aldouby, Y., Domb, A.J., and Kubek, M.J. (2009) Thyrotropin-releasing hormone d,l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo. Brain Res. 1303, 151–160.
26. Purves, D., Augustine, G.J., Fitzpatrick, D., Hall, W.C., LaMantia, A.-S., McNamara, J.O., and White, L. (2008) Neuroscience. Sunderland, MA. Sinauer Assoc.
27. Gizurarson, S. (1990). Animal models for intranasal drug delivery studies. A review article. Acta Pharm. Nord. 2, 105–122.
28. De Rosa, R., Garcia, A.A., Braschi, C., Capsoni, S., Maffei L, et al. (2005) Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc. Natl. Acad. Sci. USA 102, 3811–3816.
29. Frey, W. (2002) Intranasal delivery: bypassing the blood brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv. Technol. 151, 66–77.
30. Ross, T.M., Martinez, P.M., Renner, J.C., Thorne, R.G., Hanson, L.R., and Frey, W.H., 2nd. (2004) Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J. Neuroimmunol. 151, 66–77.
31. Thorne, R.G., and Frey, W.H., 2nd. (2001) Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 40, 907–946.
32. Thorne, R.G., Pronk, G.J., Padmanabhan, V., and Frey, W.H., 2nd. (2004) Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481–496.
33. Alcalay, R.N., Giladi, E., Pick, C.G., and Gozes, I. (2004) Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett. 361, 128–131.
34. Gozes, I., Giladi, E., Pinhasov, A., Bardea, A., and Brenneman, D.E. (2000) Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther. 293, 1091–1098.
35. Born, J., Lange, T., Kern, W., McGregor, G.P., Bickel, U., and Fehm, H.L. (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5, 514–516.
36. Capsoni, S., Giannotta, S., and Cattaneo, A. (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. USA 99, 12432–12437.
37. Chen, X.Q., Fawcett, J.R., Rahman, Y.E., Ala, T.A., and Frey, I.W. (1998) Delivery of nerve growth factor to the brain via the olfactory pathway. J. Alzheimers. Dis. 1, 35–44.
38. Gozes, I., Bardea, A., Reshef, A., Zamostiano, R., Zhukovsky, S. et al. (1996) Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc. Natl. Acad. Sci. USA 93, 427–432.
39. Illum, L. (1996) Nasal delivery. The use of animal models to predict performance in man. J. Drug Target 3, 427–442.
40. Vaccarezza, O.L., Sepich, L.N., and Tramezzani, J.H. (1981) The vomeronasal organ of the rat. J. Anat. 132, 167–185.
41. Gao, X., Tao, W., Lu, W., Zhang, Q., Zhang, Y. et al. 2006. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 27, 3482–3490.
42. Veronesi, M.C., Kubek, D.J., and Kubek M.J. (2007) Intranasal delivery of a thyrotropin-releasing hormone analog attenuates seizures in the amygdala-kindled rat. Epilepsia 48, 2280–2286.
43. Meredith, M. (2001) Human vomeronasal organ function: A critical review of best and worst cases. Chem. Senses 26, 433–445.